Cargando…
POS-005 NEUTRALIZING ANTI SARS-CoV-2 ANTIBODY RESPONSE TO COVID - 19 VACCINES: ChAdOx1-nCoV-19 AND BBV152 AMONG HAEMODIALYSIS PATIENTS
Autores principales: | Selvanathan, D., parthasarathy, R., Rohit, A., Venkatramanan, S., Dsouza, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475093/ http://dx.doi.org/10.1016/j.ekir.2022.07.020 |
Ejemplares similares
-
POS-004 NEUTRALIZING ANTI SARS-CoV-2 ANTIBODY RESPONSE TO COVID-19 VACCINES: ChAdOx1-nCoV-19 AND BBV152 AMONG HAEMODIALYSIS PATIENTS
por: Selvanathan, D., et al.
Publicado: (2022) -
Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey
por: Cherian, Somy, et al.
Publicado: (2021) -
Clinical profile of ChAdOx1 nCoV-19- and BBV152-vaccinated
individuals among hospitalized COVID-19 patients: a pair-matched
study
por: Keri, Vishakh C., et al.
Publicado: (2022) -
Neutralizing SARS-CoV-2 Antibody Response and Protective Effect of 2 Doses of ChAdOx1 nCoV-19 and BBV152 Vaccines in Hemodialysis Patients: A Preliminary Report
por: Fernando, Edwin, et al.
Publicado: (2021) -
Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study
por: Rose, Winsley, et al.
Publicado: (2023)